Travere Therapeutics (TVTX) Operating Leases (2019 - 2026)

Travere Therapeutics has reported Operating Leases for 8 years, with the latest figure at $15.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 25.94% year-over-year to $15.6 million; the trailing twelve-month figure through Mar 2026 stood at $15.6 million (down 25.94% YoY), and the FY2025 full-year result was $11.1 million, down 35.23% from the prior year.
• Operating Leases for Q1 2026 stood at $15.6 million, up from $11.1 million in the prior quarter.
• The five-year high for Operating Leases was $34.5 million in Q1 2022, with the low at $11.1 million in Q4 2025.
• Historically, Operating Leases has averaged $22.9 million across 5 years, with a median of $22.6 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Leases fell 0.02% — and 2025, when it sank 35.23%.
• Travere Therapeutics' Operating Leases stood at $27.5 million in 2022, then declined by 17.8% to $22.6 million in 2023, then fell by 23.97% to $17.2 million in 2024, then slumped by 35.23% to $11.1 million in 2025, then surged by 39.96% to $15.6 million in 2026.
• The last three Operating Leases figures came in at $15.6 million (Q1 2026), $11.1 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.